ArticleCurrent protocols2025
Epigenetic Histone Deacetylases Activity Assay in the Brain and Peripheral Organ Tissues.
Article in Current protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epigenetic histone deacetylase inhibition by sodium butyrate reduces neuroinflammation, improves neurological dysfunction and promotes disease modification of epileptogenesis following traumatic brain injury.Experimental neurology · 2026Article
- Automated analysis of postictal generalized electroencephalogram suppression for SUDEP risk stratification.Epilepsia open · 2026Article
- Epigenetic Histone Deacetylases Activity Assay in the Brain and Peripheral Organ Tissues.Current protocols · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Histone deacetylases (HDACs) are crucial epigenetic regulators involved in the modulation of gene expression and are promising therapeutic targets for treating various diseases, including central nervous system disorders and cancer. HDAC inhibitors exhibit neuroprotective, antiepileptogenic, and antidepressant properties in animal models, underscoring their clinical relevance. Quantifying HDAC activity is essential for identifying inhibitors and evaluating their effects under physiological or pathological conditions. This article outlines a comprehensive, sensitive, and robust assay to quantify HDAC activity in tissue lysates, with specific application to brain tissue. The assay is based on the catalytic removal of an acetyl group from the Boc-Lys(Ac)-AMC substrate by HDAC enzymes. Following nuclear protein extraction, tissue HDAC activity can be quantitatively assessed using a fluorometric Boc-Lys(Ac) HDAC activity kit. Adding a developer containing trypsin then converts the deacetylated product into a measurable fluorophore. This enables precise quantification of HDAC activity levels across different tissues, making the method suitable for screening putative HDAC inhibitors and assessing their effects on epigenetically modulated phenotypes. We validated these protocols using brain tissue samples from mice subjected to traumatic brain injury, a condition known to elevate HDAC activity levels. This assay provides an efficient, scalable tool for exploring HDAC function, evaluating therapeutic interventions, and advancing the understanding of HDAC-mediated mechanisms in animal models. © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Isolation of nuclear protein from brain and other tissues Support Protocol 1: Harvesting and microdissection of brain and other tissues Support Protocol 2: Estimation of extracted protein using the Pierce bicinchoninic acid (BCA) assay Basic Protocol 2: HDAC activity fluorometric assay in the brain and other tissues.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.